Here for Your Patients, for Life.
NITYR helps simplify treatment at all life’s stages, liberating your patients from medication restrictions and putting their needs first, now and in the future.
* Patients can try NITYR for 30 days, one time, for free, as long as their doctor prescribes it. Subject to terms and conditions, eligibility criteria, and other federal and state law. Terms and Conditions and eligibility criteria are available at www.nityr.us/offerstcs
NITYR helps simplify treatment at all life’s stages, liberating your patients from medication restrictions and putting their needs first, now and in the future.
Room temperature stable
Easy to give. Easy to take.
No mealtime restrictions
NITYR is the only nitisinone tablet which can be taken with or without food
Support every step of the way
100% of fully enrolled, insured patients with Hereditary Tyrosinemia Type 1 who have received NITYR have not voluntarily returned to Orfadin§2
100% of the newborn babies prescribed NITYR had their medication shipped within 24 hours, since launch3
Designed with your patients in mind, NITYR has flexible administration options to suit patients’ changing needs
Each NITYR Tablet is 20% of the volume of a single Orfadin§ (nitisinone) capsule1
The baby aspirin-size of NITYR may make it easier for toddlers to transition to swallowing their medication by themselves
MOST of the top institutions prescribing NTBC choose NITYR for their patients with HT-14
The Top 2 children’s hospitals in the US chose NITYR for their patients with HT-15
NITYR is bioequivalent to Orfadin§ (nitisinone) capsules with the:
The recommended dose of NITYR and Orfadin§ in the pediatric and adult population is 0.5 mg/kg administered orally twice daily.
Once daily dosing: NITYR can be prescribed once daily for patients 5 years of age and older who have undetectable serum and urine succinylacetone concentrations after a minimum of 4 weeks on a stable dosage of nitisinone
The room-temperature stability of NITYR tablets allows for excursions between 59° F and 86° F (15° C and 30° C) without exceeding impurity limits set by the FDA.
*For patients 5 years of age and older who have undetectable serum and urine succinylacetone concentrations after a minimum of 4 weeks on a stable dosage of nitisinone.
**30-Day Free NITYR Program: Patients can try NITYR for 30 days, one time, for free, as long as their doctor prescribes it. Subject to terms and conditions, eligibility criteria, and other federal and state law. Terms and Conditions criteria are available at www.nityr.us/offerstcs.
§Orfadin is a registered trademark, licensed by Swedish Orphan Biovitrum AB (publ) and is marketed by Sobi, Inc.
References: 1. Data on file: NIT/03/18. 2. Data on file: NIT/03/21. Data represents fully enrolled, insured NITYR patients in the US from August 2017 to February 2021 3. Data on file: NIT/03/21. US patient data from August 2017 to February 2021. 4. Data on file: NIT/03/21. US patient data from August 2017 to February 2021. Institutions ranked by Definitive Healthcare data. 5. Data on file: NIT/03/21. US patient data from August 2017 to February 2021. Institutions ranked by U.S. News: Best Children’s Hospitals 2020-21. 6. Data on file: NIT/02/20. 7. Data on file: NIT/01/20